P Meyer-Wilmes, J Huober, M Untch, J-U Blohmer, W Janni, C Denkert, P Klare, T Link, K Rhiem, C Bayer, M Reinisch, V Bjelic-Radisic, D M Zahm, C Hanusch, C Solbach, G Heinrich, A D Hartkopf, A Schneeweiss, P Fasching, N Filmann, V Nekljudova, J Holtschmidt, E Stickeler, S Loibl
BACKGROUND: The GENEVIEVE study, comparing neoadjuvant cabazitaxel versus paclitaxel in triple-negative breast cancer (TNBC) and luminal B/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC), previously reported significant differences in pathological complete response (pCR) rates. Effects on long-term outcome are unknown. PATIENTS AND METHODS: GENEVIEVE randomized patients with cT2-3, any cN or cT1, cN+/pNSLN +, centrally confirmed TNBC or luminal B/HER2-negative BC (latter defined as estrogen/progesterone receptor-positive and >14% Ki-67-stained cells) to receive either cabazitaxel 25 mg/m2 q3w for four cycles or paclitaxel 80 mg/m2 weekly for 12 weeks...
April 24, 2024: ESMO Open